RedHill Biopharma Ltd. Company Profile

News Articles [ 598 Associated News Articles listed on BioPortfolio]

RedHill Biopharma Announces a Successful Pivotal Bioequivalence Trial with RHB-103 for the ...

The Trial Met its Specified Endpoints and Demonstrated Bioequivalence Between RedHill Biopharma's Oral Thin-Film RHB-103 and Merck & Co.'s Leading Rizatriptan Drug with Annual Sales Exceeding...

[RedHill BioPharma] private placement brings in $6.5mm

[RedHill Biopharma Ltd.] (developing new formulations of existing drugs) netted $6.5mm through the private sale of 6.5mm shares at $1.05 each (a slight premium). Buyers included the Koramic Finance Co...

Bioassociate Initiated Coverage On RedHill Biopharma With A Buy

By Tiran Rothman: Company overview & Investment thesis RedHill Biopharma (RDHL) is a biopharmaceutical company focused on development of late clinical-stage new, improved, and patented formulat...

RedHill submits NDA for migraine product

IntelGenx Corp. (TSX-V:IGX; OTCBB:IGXT) and partner RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said RedHill submitted an NDA to FDA for RHB-103 to treat acute migraine. The NDA was submitted...

Positive data expected for RedHill Biopharma's Crohn's disease candidate

Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill Biopharma (TASE: RDHL) with a "Buy" rating and a $20share price target, saying their impetus f...

RedHill Biopharma lists on NASDAQ

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) listed its American Depository Shares on NASDAQ without raising money on Thursday. Each ADS represents 10 ordinary shares. RedHill said it believes...

RedHill Biopharma to Present at the 25th Annual ROTH Conference

TEL-AVIV, Israel, March 6, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on t...

RedHill Biopharma Reports Financial Results for the First Quarter of 2013

The Company Maintains a Strong Balance Sheet Following Submission to the FDA of Its First New Drug Application (NDA) for RHB-103 (Migraine) RedHill Plans to Submit a Second NDA, for RHB-102 (Onc...

Drugs and Medications [ 6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [ 17 Associated PubMed Articles listed on BioPortfolio]

Fostering a new dialogue to improve access to finance for European biopharma SMEs.

This article reviews the current economic crisis as it impacts upon European biopharma SMEs and their ability to secure investment and funding. In particular it presents an analysis of a broader, pre-...

Workload, referral characteristics and consultation outcomes of out-of-hours ophthalmology services.

CPAP can be considered as an alternative to intubation and surfactant treatment in extremely preterm infants.

FOCAL THERAPY FOR RENAL MASS LESIONS: WHERE DO WE STAND IN 2012?

A selective and convenient method for the synthesis of 2-phenylaminothiazolines.

A series of 2-phenylaminothiazolines have been prepared from the corresponding N-(2-hydroxyethyl)-N'-phenylthioureas under mild reaction conditions using either thio-CDI (1,1'-thiocarbonyldiimidazole)...

Clinical Trials [ 3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [ 91 Associated Companies listed on BioPortfolio]

RedHill Biopharma Ltd.

RedHill Biopharma is an Israeli pharmaceutical company focused primarily on acquisition and development of late clinical-stage new formulations of existing drugs. For more informa...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights...

BioPharma Fund

BioPharma Fund is an investment fund that invests in shares of medical biotechnology companies. Biotechnology companies are developing new drugs for many diseases such as cancer, heart disease, diabet...